Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.860
-0.040 (-2.11%)
Jun 25, 2026, 11:38 AM EDT - Market open
Innate Pharma Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Innate Pharma stock has a consensus rating of "Buy" and an average price target of $6.00. The average 1-year stock price forecast is 222.58% higher than the current stock price, while the lowest is $3.00 (+61.29%) and the highest is $8.00 (+330.11%).
Price Target: $6.00 (+222.58%)
Analyst Consensus: Buy
* Price targets were last updated on May 14, 2026.
Analyst Ratings
The average analyst rating for Innate Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $5 | Buy | Reiterates | $5 | +168.82% | May 14, 2026 |
| BTIG | BTIG | Buy Maintains $8 | Buy | Maintains | $8 | +330.11% | May 14, 2026 |
Financial Forecast
Revenue This Year
31.21M
from 9.01M
Increased by 246.64%
Revenue Next Year
64.75M
from 31.21M
Increased by 107.43%
EPS This Year
0.95
EPS Next Year
2.15
from 0.95
Increased by 126.32%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 100.0M | ||
| Avg | 31.2M | ||
| Low | 4.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1,010.5% | ||
| Avg | 246.6% | ||
| Low | -53.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 0.95 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |